dc.contributor.author |
Kenmogne, Vanelle L
|
|
dc.contributor.author |
Nweke, EE
|
|
dc.contributor.author |
Takundwa, Mutsa M
|
|
dc.contributor.author |
Fru, PN
|
|
dc.contributor.author |
Thimiri Govindaraj, Deepak B
|
|
dc.date.accessioned |
2023-04-11T06:41:45Z |
|
dc.date.available |
2023-04-11T06:41:45Z |
|
dc.date.issued |
2022-10 |
|
dc.identifier.citation |
Kenmogne, V.L., Nweke, E., Takundwa, M.M., Fru, P. & Thimiri Govinda Raj, D.B. 2022. Application of drug repurposing-based precision medicine platform for leukaemia patient treatment. <i>Advances in Experimental Medicine and Biology.</i> http://hdl.handle.net/10204/12731 |
en_ZA |
dc.identifier.issn |
0065-2598 |
|
dc.identifier.issn |
2214-8019 |
|
dc.identifier.uri |
https://doi.org/10.1007/5584_2022_744
|
|
dc.identifier.uri |
http://hdl.handle.net/10204/12731
|
|
dc.description.abstract |
Drug resistance in leukaemia is a major problem that needs to be addressed. Precision medicine provides an avenue to reduce drug resistance through a personalised treatment plan. It has helped to better stratify patients based on their molecular profile and therefore improved the sensitivity of patients to a given therapeutic regimen. However, therapeutic options are still limited for patients who have already been subjected to many lines of chemotherapy. The process of designing and developing new drugs requires significant resources, including money and time. Drug repurposing has been explored as an alternative to identify effective drug(s) that could be used to target leukaemia and lessen the burden of drug resistance. The drug repurposing process usually includes preclinical studies with drug screening and clinical trials before approval. Although most of the repurposed drugs that have been identified are generally safe for leukaemia treatment, they seem not to be good candidates for monotherapy but could have value in combination with other drugs, especially for patients who have exhausted therapeutic options. In this review, we highlight precision medicine in leukaemia and the role of drug repurposing. Specifically, we discuss the several screening methods via chemoinformatic, in vitro, and ex vivo that have facilitated and accelerated the drug repurposing process. |
en_US |
dc.format |
Abstract |
en_US |
dc.language.iso |
en |
en_US |
dc.relation.uri |
https://link.springer.com/chapter/10.1007/5584_2022_744 |
en_US |
dc.source |
Advances in Experimental Medicine and Biology |
en_US |
dc.subject |
Drug repurposing |
en_US |
dc.subject |
Drug screening |
en_US |
dc.subject |
Leukaemia |
en_US |
dc.subject |
Precision medicine |
en_US |
dc.title |
Application of drug repurposing-based precision medicine platform for leukaemia patient treatment |
en_US |
dc.type |
Article |
en_US |
dc.description.pages |
12pp |
en_US |
dc.description.note |
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG. Due to copyright restrictions, the attached PDF file only contains the abstract of the full-text item. For access to the full-text item, please consult the publisher's website: https://link.springer.com/chapter/10.1007/5584_2022_744 |
en_US |
dc.description.cluster |
Next Generation Health |
en_US |
dc.description.impactarea |
Synthetic Nanobiotech Biomachs |
en_US |
dc.identifier.apacitation |
Kenmogne, V. L., Nweke, E., Takundwa, M. M., Fru, P., & Thimiri Govinda Raj, D. B. (2022). Application of drug repurposing-based precision medicine platform for leukaemia patient treatment. <i>Advances in Experimental Medicine and Biology</i>, http://hdl.handle.net/10204/12731 |
en_ZA |
dc.identifier.chicagocitation |
Kenmogne, Vanelle L, EE Nweke, Mutsa M Takundwa, PN Fru, and Deepak B Thimiri Govinda Raj "Application of drug repurposing-based precision medicine platform for leukaemia patient treatment." <i>Advances in Experimental Medicine and Biology</i> (2022) http://hdl.handle.net/10204/12731 |
en_ZA |
dc.identifier.vancouvercitation |
Kenmogne VL, Nweke E, Takundwa MM, Fru P, Thimiri Govinda Raj DB. Application of drug repurposing-based precision medicine platform for leukaemia patient treatment. Advances in Experimental Medicine and Biology. 2022; http://hdl.handle.net/10204/12731. |
en_ZA |
dc.identifier.ris |
TY - Article
AU - Kenmogne, Vanelle L
AU - Nweke, EE
AU - Takundwa, Mutsa M
AU - Fru, PN
AU - Thimiri Govinda Raj, Deepak B
AB - Drug resistance in leukaemia is a major problem that needs to be addressed. Precision medicine provides an avenue to reduce drug resistance through a personalised treatment plan. It has helped to better stratify patients based on their molecular profile and therefore improved the sensitivity of patients to a given therapeutic regimen. However, therapeutic options are still limited for patients who have already been subjected to many lines of chemotherapy. The process of designing and developing new drugs requires significant resources, including money and time. Drug repurposing has been explored as an alternative to identify effective drug(s) that could be used to target leukaemia and lessen the burden of drug resistance. The drug repurposing process usually includes preclinical studies with drug screening and clinical trials before approval. Although most of the repurposed drugs that have been identified are generally safe for leukaemia treatment, they seem not to be good candidates for monotherapy but could have value in combination with other drugs, especially for patients who have exhausted therapeutic options. In this review, we highlight precision medicine in leukaemia and the role of drug repurposing. Specifically, we discuss the several screening methods via chemoinformatic, in vitro, and ex vivo that have facilitated and accelerated the drug repurposing process.
DA - 2022-10
DB - ResearchSpace
DP - CSIR
J1 - Advances in Experimental Medicine and Biology
KW - Drug repurposing
KW - Drug screening
KW - Leukaemia
KW - Precision medicine
LK - https://researchspace.csir.co.za
PY - 2022
SM - 0065-2598
SM - 2214-8019
T1 - Application of drug repurposing-based precision medicine platform for leukaemia patient treatment
TI - Application of drug repurposing-based precision medicine platform for leukaemia patient treatment
UR - http://hdl.handle.net/10204/12731
ER - |
en_ZA |
dc.identifier.worklist |
26363 |
en_US |